PMID- 15733104
OWN - NLM
STAT- MEDLINE
DCOM- 20050721
LR  - 20151119
IS  - 0919-8172 (Print)
IS  - 0919-8172 (Linking)
VI  - 12
IP  - 2
DP  - 2005 Feb
TI  - Proliferative activity and genetic changes in adrenal cortical tumors examined by 
      flow cytometry, fluorescence in situ hybridization and immunohistochemistry.
PG  - 121-7
AB  - BACKGROUND: To determine differences in biological features among different 
      adrenal tumors, we investigated the DNA ploidy, numerical chromosomal aberration 
      and proliferative activity in human adrenal cortical neoplasms. METHODS: Our 
      study included six adrenal cortical adenomas with Cushing syndrome, 12 adenomas 
      with hyperaldosteronism, three non-functioning adenomas and three adrenal 
      cortical carcinomas. Isolated nuclei from frozen samples were used for 
      fluorescence in situ hybridization (FISH) analysis, and formalin-fixed, 
      paraffin-embedded tissues from the same materials were analyzed using flow 
      cytometry (FCM) for DNA ploidy. Sections from paraffin blocks were stained 
      immunohistochemically with antibodies against Ki-67 and p53. For FISH analysis, 
      we used an alpha-centromeric enumeration probe for chromosome 17. RESULTS: The 
      mean Ki-67 labeling index (LI) of adrenal cortical carcinomas was markedly higher 
      than that of adrenal cortical adenomas (209.4 vs 8.7). In functional adrenal 
      cortical adenomas, the LI was significantly lower in adenomas with 
      hyperaldosteronism than in those with Cushing syndrome (P = 0.004), although FCM 
      results indicated that tetraploid patterns were more frequently observed in the 
      former type. Tumor size was significantly smaller in adenomas with 
      hyperaldosteronism than in those with Cushing syndrome (P = 0.004). Chromosome 17 
      showed disomy in all adrenal cortical adenomas, whereas chromosome 17 
      abnormalities were found in two of three adrenal cortical carcinomas. Only the 
      latter two cases strongly expressed p53 protein. CONCLUSIONS: Our study 
      characterized various biological features of benign and malignant adrenal 
      cortical tumors. The use of a combination of markers might provide additional 
      information to assist our understanding of the clinical behavior of an individual 
      adrenal cortical tumor.
FAU - Takehara, Kousuke
AU  - Takehara K
AD  - Division of Nephro-Urology, Nagasaki University Graduate School of Biomedical 
      Sciences, Nagasaki, Japan.
FAU - Sakai, Hideki
AU  - Sakai H
FAU - Shono, Takefumi
AU  - Shono T
FAU - Irie, Junji
AU  - Irie J
FAU - Kanetake, Hiroshi
AU  - Kanetake H
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Int J Urol
JT  - International journal of urology : official journal of the Japanese Urological 
      Association
JID - 9440237
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (DNA, Neoplasm)
RN  - 0 (Ki-67 Antigen)
RN  - 0 (Tumor Suppressor Protein p53)
SB  - IM
MH  - Adenoma/genetics/metabolism/pathology
MH  - Adrenal Cortex Neoplasms/*genetics/*metabolism/pathology
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/genetics/metabolism
MH  - Carcinoma/genetics/metabolism/pathology
MH  - Cell Proliferation
MH  - Chromosomes, Human, Pair 17
MH  - Cushing Syndrome/genetics/metabolism/pathology
MH  - DNA, Neoplasm/genetics
MH  - Female
MH  - *Flow Cytometry
MH  - Humans
MH  - Hyperaldosteronism/genetics/metabolism/pathology
MH  - *Immunohistochemistry
MH  - *In Situ Hybridization, Fluorescence
MH  - Ki-67 Antigen/metabolism
MH  - Male
MH  - Middle Aged
MH  - Ploidies
MH  - Tumor Suppressor Protein p53/metabolism
EDAT- 2005/03/01 09:00
MHDA- 2005/07/22 09:00
CRDT- 2005/03/01 09:00
PHST- 2005/03/01 09:00 [pubmed]
PHST- 2005/07/22 09:00 [medline]
PHST- 2005/03/01 09:00 [entrez]
AID - IJU999 [pii]
AID - 10.1111/j.1442-2042.2005.00999.x [doi]
PST - ppublish
SO  - Int J Urol. 2005 Feb;12(2):121-7. doi: 10.1111/j.1442-2042.2005.00999.x.